Bipolar II disorder: An overview of recent developments

Canadian Journal of Psychiatry

Volumn 49, Issue 12, 2004, Pages 802-812

  Hadjipavlou, George ^a   Mok, Hiram ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bipolar II disorder; Bipolar spectrum disorder; Diagnosis; Subsyndromal symptoms; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE;

BEHAVIOR THERAPY; BIPOLAR II DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; HUMAN; MEDICAL LITERATURE; MEDLINE; PRACTICE GUIDELINE; PREVALENCE; PSYCHOTHERAPY; REVIEW; SCREENING TEST; SYMPTOM;

EID: 12744273385     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404901203     Document Type: Review

References (98)

1. Akiskal HS, Pinto O. The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr Clin North Am 1999;22:517-34, vii.
2. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002;47:125-34.
3. Katzow JJ, Hsu DJ, Nassir GS. The bipolar spectrum: a clinical perspective. Bipolar Disord 2003;5:436-42.
4. Benazzi F, Akiskal HS. Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania. J Affect Disord 2003;73:33-8.
5. Piver A, Yatham LN, Lam RW. Bipolar spectrum disorders. New perspectives. Can Fam Physician 2002;48:896-904.
6. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: focus on the cyclothymic, anxious-sensitive, impulse-dyscontrol, and binge-eating connection in bipolar II and related conditions. Psychiatr Clin North Am 2002;25:713-37.
7. Benazzi F. Is 4 days the minimum duration of hypomania in bipolar II disorder? Eur Arch Psychiatry Clin Neurosci 2001;251:32-4.
8. Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord 2003;73:133-46.
9. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003;73:123-31.
10. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000;59(Suppl 1):S5-S30.
11. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998;50:143-51.
12. Hantouche EG, Akiskal HS, Lancrenon S, Allilaire JF, Sechter D, Azorin JM, and others. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord 1998;50:163-73.
13. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, and others. Long-term symptomatic status of bipolar I vs bipolar II disorders. Int J Neuropsychopharmacol 2003;6:127-37.
14. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, and others. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9.
15. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 2004;6:62-6.
16. Benazzi F. Course and outcome of bipolar II disorder: a retrospective study. Psychiatry Clin Neurosci 2001;55:67-70.
17. Vieta E, Colom F, Martinez-Aran A, Benabarre A, Reinares M, Gasto C. Bipolar II disorder and comorbidity. Compr Psychiatry 2000;41:339-43.
18. Joyce PR, Luty SE, McKenzie JM, Mulder RT, McIntosh W, Carter FA, and others. Bipolar II disorder: personality and outcome in two clinical samples. Aust N Z J Psychiatry 2004;38:433-8.
19. Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder. Bipolar Disord 2003;5:456-63.
20. Benazzi F. Toward better probing for hypomania of bipolar-II disorder by using Angst's checklist. Int J Methods Psychiatr Res 2004;13:1-9.
21. Benazzi F. Validating Angst's "ups & downs" personality trait as a new marker of bipolar II disorder. Eur Arch Psychiatry Clin Neurosci 2004;254:48-54.
22. Benazzi F. Bipolar II disorder family history using the family history screen: findings and clinical implications. Compr Psychiatry 2004;45:77-82.
23. Benazzi F. Underdiagnosis of bipolar II disorders in the community. J Clin Psychiatry 2003;64:1130-1.
24. Simpson SG, McMahon FJ, McInnis MG, MacKinnon DF, Edwin D, Folstein SE, and others. Diagnostic reliability of bipolar II disorder. Arch Gen Psychiatry 2002;59:736-40.
25. Angst J, Gamma A, Benazzi F, et al. Diagnostic issues in bipolar disorder. Eur Neuropsychopharmacol 2003;13(Suppl 2):S43-S50.
26. Benazzi F. The clinical picture of bipolar II outpatient depression in private practice. Psychopathology 2001;34:81-4.
27. Isometsa E, Suominen K, Mantere O, Valtonen H, Leppamaki S, Pippingskold M, and others. The mood disorder questionnaire improves recognition of bipolar disorder in psychiatric care. BMC Psychiatry 2003;3:8.
28. Suppes T, Dennehy EB. Evidence-based long-term treatment of bipolar II disorder. J Clin Psychiatry 2002;63(Suppl 10):29-33.
29. Hadjipavlou G, Mok H, Yatham LN. Pharmacotherapy of bipolar II disorder: a critical review of current evidence. Bipolar Disord 2004;6:14-25.
30. Amsterdam JD, Brunswick DJ. Antidepressant monotherapy for bipolar type II major depression. Bipolar Disord 2003;5:388-95.
31. Amsterdam JD, Shults J, Brunswick DJ, Hundert M. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar Disord 2004;6:75-81.
32. Calabrese JR, Suppes T, Bowden CL, Sach GS, Swann AC, McElroy SL, and others. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
33. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64:403-7.
34. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001;67:207-12.
35. Vieta E, Sanchez-Moreno J, Goikolea JM, Torrent C, Benabarre A, Colom F, and others. Adjunctive topiramate in bipolar II disorder. World J Biol Psychiatry 2003;4:172-6.
36. Janenawasin S, Wang PW, Lembke A, Schumacher M, Das B, Santosa CM, and others. Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Bipolar Disord 2002;4:328-34.
37. Zarate CA, Jr., Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, and others. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
38. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-41.
39. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976;11:31-42.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association; 1994.
41. Baldessarini RJ. A plea for integrity of the bipolar disorder concept. Bipolar Disord 2000;2:3-7.
42. Goodwin G. Hypomania: what's in a name? Br J Psychiatry 2002;181:94-5.
43. Cassano GB, Rucci P, Frank E, Fagiolini A, Dell'Osso L, Shear MK, and others. The mood spectrum in unipolar and bipolar disorder: arguments for a unitary approach. Am J Psychiatry 2004;161:1264-9.
44. Chun BJ, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6:32-42.
45. Alda M. The phenotypic spectra of bipolar disorder. Eur Neuropsychopharmacol 2004;14(Suppl 2):S94-S99.
46. Ghaemi SN, Sachs GS, Chiou AM, Pandurangi AK, Goodwin K, Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord 1999;52:135-44.
47. Benazzi F. Sensitivity and specificity of clinical markers for the diagnosis of bipolar II disorder. Compr Psychiatry 2001;42:461-5.
48. Cassano GB, Dell'Osso L, Frank E, Miniati M, Fagiolini A, Shear K, and others. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord 1999;54:319-28.
49. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord 2003;5:421-33.
50. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, and others. Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 1994;51:826-36.
51. Pini S, Cassano GB, Dell'Osso L, Amador XF. Insight into illness in schizophrenia, schizoaffective disorder, and mood disorders with psychotic features. Am J Psychiatry 2001;158:122-5.
52. Benazzi F. Prevalence of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord 1997;43:163-6.
53. Coryell W, Endicott J, Maser JD, Keller MB, Leon AC, Akiskal HS. Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 1995;152:385-90 (initially 40)
54. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE, and others. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000;157:1873-5.
55. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, and others. Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 1995;52:114-23.
56. Benazzi F. Prevalence of bipolar II disorder in atypical depression. Eur Arch Psychiatry Clin Neurosci 1999;249:62-5.
57. Magill CA. The boundary between borderline personality disorder and bipolar disorder: current concepts and challenges. Can J Psychiatry 2004;49:551-6.
58. Benazzi F. Borderline personality disorder and bipolar II disorder in private practice depressed outpatients. Compr Psychiatry 2000;41:106-10.
59. Perugi G, Toni C, Frare F, Travierso MC, Hantouche E, Akiskal HS. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome. J Clin Psychiatry 2002;63:1129-34.
60. Coryell W, Endicott J, Reich T, Andreason N, Keller M. A family study of bipolar II disorder. Br J Psychiatry 1984;145:49-54.
61. Simpson SG, Folstein SE, Meyers DA, McMahon FJ, Brusco DM, DePaulo JR. Bipolar II: the most common bipolar phenotype? Am J Psychiatry 1993;150:901-3.
62. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 1998;155:638-45.
63. Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999;22:667-73, ix-x.
64. Rihmer Z, Kiss K. Bipolar disorders and suicidal behaviour. Bipolar Disord 2002;4(Suppl 1):21-5.
65. Baldessarini RJ, Tondo L, Floris G, Hennen J. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. J Affect Disord 2000;61:13-22.
66. MacQueen GM, Young LT. Bipolar II disorder: symptoms, course, and response to treatment. Psychiatr Serv 2001;52:358-61.
67. Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003;5:407-20.
68. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry 2000;48:558-72.
69. Thase ME, Bhargava M, Sachs GS. Treatment of bipolar depression: current status, continued challenges, and the STEP-BD approach. Psychiatr Clin North Am 2003;26:495-518.
70. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000;57:187-90.
71. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:1-50.
72. Sharma V, Yatham LN, Haslam DR, Silverstone PH, Parikh SV, Matte R, and others. Continuation and prophylactic treatment of bipolar disorder. Can J Psychiatry 1997;42(Suppl 2):92S-100S.
73. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-22.
74. Dunner DL, Stallone F, Fieve RR. Prophylaxis with lithium carbonate: an update. Arch Gen Psychiatry 1982;39:1344-5.
75. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976;133:925-9.
76. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065-9.
77. Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF. Prophylactic effect of lithium and imipramine in unipolar and bipolar II patients: a preliminary report. Am J Psychiatry 1978;135:570-2.
78. Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry Suppl 2001;41:S184-S190.
79. Tondo L, Baldessarini RJ, Floris G, Rudas N. Effectiveness of restarting lithium treatment after its discontinuation in bipolar I and bipolar II disorders. Am J Psychiatry 1997;154:548-50.
80. Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999;14:283-5.
81. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000;42(Suppl 1):2-10.
82. Suppes T, Browb ES, McElroy SL, Keck PE Jr, Nolen W, Kupka R, and others. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999;53:95-8.
83. Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998;59:426-9.
84. Vieta E, Gasto C, Colom F, Reinares M, Martinez-Aran A, Benabarre A, and others. Role of risperidone in bipolar II: an open 6-month study. J Affect Disord 2001;67:213-9.
85. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8.
86. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 2002;105:427-30.
87. Coryell W, Solomon D, Turvey C, Keller M, Leon AC, Endicott J, and others. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003;60:914-20.
88. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997;46:73-7.
89. Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:414-7.
90. Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord 2000;59:225-9.
91. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum, and others. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 1998;18:435-40.
92. Jones S. Psychotherapy of bipolar disorder: a review. J Affect Disord 2004;80:101-14.
93. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, and others. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402-7.
94. Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, and others. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003;64:1101-5.
95. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
96. Haykal RF, Akiskal HS. Bupropion as a promising approach to rapid cycling bipolar II patients. J Clin Psychiatry 1990;51:450-5.
97. Vieta E, Martineq-Aran A, Goikolea J, Torrent C, Colom F, Benagarre A, Reinares M, and others. A randomized train comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-12.
98. Yatham LN. Newer anticonvulsants in the treatment of bipolar disorder. J Clin Psychiatry 2004;65(Suppl 10):28-35.